Our Team

Pedram Argani, M.D.

Pedram Argani, MD is a Professor of Pathology and Oncology at the Johns Hopkins University School of Medicine, Baltimore, Maryland. He earned his MD degree from The University of Pennsylvania, and completed residency training in Anatomic Pathology at the Hospital of The University of Pennsylvania. Following fellowships in Oncologic Pathology and Molecular Pathology at Memorial Sloan-Kettering Cancer Center, Dr. Argani joined the faculty of the The Johns Hopkins University School of Medicine Department of Pathology in 1997. He received the 2007 Arthur Purdy Stout Society award for accomplishments by a surgical pathologist under the age of 45 years, and was selected as a Top Cancer Doctor for 2015 by Castle Connolly for Newsweek Health.

Dr. Argani described the Xp11 translocation renal cell carcinomas and the t(6;11) renal cell carcinomas in 2001. The Xp11 translocation renal cell carcinomas were accepted as distinctive entity by the 2004 World Health Organization (WHO) classification of renal neoplasia, while the t(6;11) renal cell carcinomas will be recognized in the upcoming 2016 WHO renal tumor classification.

Following Dr. Argani's initial discovery of these neoplasms, he has performed studies to delineate the clinical behavior of these neoplasms, as well as their responses to therapy. He has developed immunohistochemical and fluorescence in situ hybridization (FISH) assays which can be used to identify these neoplasms in routine pathology material. He has identified therapeutic targets in these neoplasms, such as C-met overexpression and mTOR pathway activation.

Through his pathology consultation service, Dr. Argani maintains the world's largest documented collection of these neoplasms, and has created tissue microarrays harboring many of these neoplasms to expedite further molecular characterization. Dr. Argani's laboratory is actively searching for therapeutic targets in these neoplasms which will improve patient outcome. He can be reached at [email protected].